Argenx to Acquire US Synthetic Peptides Developer Unnatural Products for Up to $1.2 Billion

MT Newswires · 11/09 01:35
01:35 AM EST, 11/09/2026 (MT Newswires) -- Argenx (ARGX.BR) agreed to acquire US-based synthetic macrocyclic peptides developer Unnatural Products in a deal valued at up to $1.15 billion, according to a Monday release. Under the transaction, the immunology company, which currently owns a minority stake in Unnatural Products, will acquire the target company for an upfront payment of $550 million in cash and up to $595 million in payments tied to certain milestones. Subject to customary closing conditions, the acquisition is expected to close by the end of 2026. Following closing, Unnatural Products will continue operating from its Santa Cruz, California, site as part of Argenx's global research organization.